Figure 1
From: ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury
Effect of ARA290 on clinical markers of renal function. No differences were found in plasma creatinine levels (1A) or urine flow (1B) between vehicle- or ARA290 treated animals. The GFR of ARA290 treated animals was significantly increased in the first seven days post-reperfusion. ARA290 resulted in immediate renal function, while control kidneys started functioning after 48 hours (1C, p<0.05).